[Pharmacokinetics of sulfaclomide in man under therapeutically relevant conditions].
Pharmacokinetic parameters of the long-term sulfanilamide Sulfaclomid (4-[4-aminobenzensulphonamido]2,6-dimethyl-5-chlorpyrimidine) were determined in 25 female subjects. Both the elimination half-life of Sulfaclomid in the serum and the maximum acetylation rate in the urine are genetically determined. They show a polymodal behavior. The half-life is unrelated to the protein binding, which shows considerable individual differences in the therapeutic relevant range of about 200 microgram/ml serum. This confirms the human pharmacological postulate according to pharmacokinetical dosage schedules including genetic factors. An individual therapy service is necessary in certain drugs and in highly endangered groups of patients.
D000107:Acetylation; D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D011485:Protein Binding; D011743:Pyrimidines / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use / Q000652:urine; D013424:Sulfanilamides / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use / Q000652:urine; D000096926:Benzenesulfonamides
D001798:Blood Proteins; D011743:Pyrimidines; D013424:Sulfanilamides; C005740:sulfaclomide; D000096926:Benzenesulfonamides
Zur Pharmakokinetik von Sulfaclomid beim Menschen unter therapeutisch relevantne Aspekten.